Shattuck Labs, Inc. (STTK)

US — Healthcare Sector
Peers: CCCC  ELYM  PRLD  GLUE  FHTX  KYMR  NRIX  PRDS  CSBR  IPSC  PMVP  STOK 

Automate Your Wheel Strategy on STTK

With Tiblio's Option Bot, you can configure your own wheel strategy including STTK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol STTK
  • Rev/Share 0.3747
  • Book/Share 1.3261
  • PB 0.7616
  • Debt/Equity 0.0335
  • CurrentRatio 9.0776
  • ROIC -1.0724

 

  • MktCap 48382232.0
  • FreeCF/Share -1.1075
  • PFCF -0.8572
  • PE -0.729
  • Debt/Assets 0.0294
  • DivYield 0
  • ROE -0.7969

 

  • Rating B-
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation STTK Leerink Partners -- Outperform -- $4 March 17, 2025
Downgrade STTK Citigroup Buy Neutral $8 $2 Oct. 2, 2024
Downgrade STTK Needham Buy Hold -- -- Oct. 2, 2024
Downgrade STTK H.C. Wainwright Buy Neutral -- -- Oct. 1, 2024

News

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
STTK
Published: March 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class blocking antibody to DR3, the receptor for TL1A; data demonstrated favorable safety profile, full receptor occupancy, lack of DR3 agonism –

Read More
image for news Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
STTK
Published: February 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxicology study – – SL-325 receptor occupancy (RO) and pharmacokinetic (PK) profile observed suggestive of extended dosing intervals; IND filing expected in the third quarter of 2025 – AUSTIN, TX & DURHAM, NC, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, …

Read More
image for news Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025
STTK
Published: February 13, 2025 by: GlobeNewsWire
Sentiment: Neutral

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming oral presentation at the 20th Congress of ECCO in Inflammatory Bowel Diseases 2025 being held in Berlin, Germany from February 19–22, 2025. This presentation will feature results from the IND-enabling toxicology studies of SL-325, a first-in-class DR3 blocking antibody, in non-human primates.

Read More
image for news Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

About Shattuck Labs, Inc. (STTK)

  • IPO Date 2020-10-09
  • Website https://www.shattucklabs.com
  • Industry Biotechnology
  • CEO Dr. Taylor H. Schreiber M.D., Ph.D.
  • Employees 44

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.